Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies

International Immunology

Volumn 9, Issue 9, 1997, Pages 1281-1290

  Hioe, Catarina E ^a   Xu, Serena ^a   Chigurupati, Padmasree ^a,c   Burda, Sherri ^a   Williams, Constance ^b   Gorny, Miroslaw K ^a   Zolla Pazner, Susan ^a,b  

^a NEW YORK UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c 222 Langhmir Labs   (United States)

Author keywords

AIDS; Immunity; Neutralizing epitopes

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD4 ANTIGEN; EPITOPE; GLYCOPROTEIN GP 120; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; HIV ANTIBODIES; HIV ANTIGENS; HIV-1; HUMANS; IMMUNE SERA; NEUTRALIZATION TESTS;

EID: 0030825573     PISSN: 09538178     EISSN: None     Source Type: Journal    
DOI: 10.1093/intimm/9.9.1281     Document Type: Article

References (74)

1. Robey, W. G., Safai, B., Oroszlan, S., Arthur, L. O., Gonda, M. A., Gallo, R. C. and Fischinger, P. J. 1985. Characterization of envelope and core structural gene products of HTLV-III with sera from AIDS patients. Science 228:593.
2. Gaines, H., von Sydow, M., Sönnerborg, A., Albert, J., Czajkowski, J., Pehrson, P. O., Chiodi, F., Moberg, L., Fenyö, E.-M., Åsjö, B. and Forsgren, M. 1987. Antibody response in primary human immunodeficiency virus infection. Lancet i:1249.
3. Horsburgh, C. R., Jr, Ou, C. Y., Jason, J., Holmberg, S. D., Longini, I. M., Jr, Schable, C., Mayer, K. H., Lifson, A. R., Schochetman, G., Ward, J. W., Rutherford, G. W., Evatt, B. L., Seage, G. R., III and Jaffe, H. W. 1989. Duration of human immunodeficiency virus infection before detection of antibody. Lancet ii:637.
4. Albert, J., Abrahamsson, B., Nagy, K., Aurelius, E., Gaines, H., Nyström, G. and Fenyö, E. M. 1990. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 4:107.
5. Lathey, J. L., Pratt, R. D. and Spector, S A. 1997. Appearance of autologous neutralizing antibody correlates with reduction in virus load and phenotype switch during primary infection with human immunodeficiency virus type 1. J. Infect. Dis. 175:231.
6. Poignard, P., Klasse, P. J. and Sattentau, Q. J. 1996. Antibody neutralization of HIV-1. Immunol. Today 17:239.
7. Loofbourow J. C., Cabasso, V. J., Roby, R. E. and Anuskiewicz, W. 1971. Rabies immune globulin (human) clinical trials and dose determination. J. Am. Med. Ass. 217:1825.
8. Iwarson, S., Ahlmen, J., Eriksson, E., Hermodsson, S., Kjellman, H., Ljunggren, C. and Selander, D. 1977. Hepatitis B immune globulin in prevention of hepatitis B among hospital staff members. J. Infect. Dis. 135:473.
9. Groothuis, J. R., Levin, M. J., Rodriguez, W., Hall, C. B., Long, C. E., Kim, H. W., Lauer, B. A. and Hemming, V. G. 1991. Use of intravenous gamma globulin to passively immunize high risk children against respiratory syncytial virus: safety and pharmacokinetics. Antimicrob. Ag. Chemother 35:1469.
10. Prince, A. M., Reesink, H., Pascual, D., Horowitz, B., Hewlett, I., Murthy, K. K., Cobb, K. E. and Eichberg, J. W. 1991. Prevention of HIV infection by passive immunization with HIV immunoglobulin. AIDS Res. Hum. Retroviruses 7:971
11. Emini E. A., Schleif, W. A., Nunberg, J. H., Conley, A. J., Eda, Y., Tokiyoshi, S., Putney, S. D., Matsushita, S., Cobb, K. E., Jett, C. M., Eichberg, J. W. and Murthy, K. K. 1992. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 355:728.
12. Safrit, J. T., Fung, M. S. C., Andrews, C. A., Braun, D. G., Sun, W. N. C., Chang, T. W. and Koup, R. A. 1993. hu-PBL-SCID mice can be protected from HIV-1 infection by passive transfer of monoclonal antibody to the principal neutralizing determinant of envelope gp120. AIDS 7:15.
13. Gauduin, M.-C., Safrit, J. T., Weir, R., Fung, M. S. C, and Koup, R. A. 1995, Pre- and post-exposure protection against human immunodeficiency virus type 1 infection mediated by a monoclonal antibody. J. Infect. Dis. 171:1203.
14. Ugen, K. E., Goedert, J. J., Boyer, J., Refaeli, Y., Frank, I., Williams, W. V., Willoughby, A., Landesman, S., Mendez, H., Rubinstein, A., Kieber-Emmons, T. and Weiner, D. B. 1992. Vertical transmission of human immunodeficiency virus (HIV) infection. Reactivity of maternal sera with glycoprotein 120 and 41 peptides from HIV type 1. J. Clin. Invest. 89:1923.
15. Scarlatti, G., Albert, J., Rossi, P, Hodara, V., Biraghi, P., Muggiasca, L. and Fenyö, E. M. 1993. Mother to child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates. J. Infect Dis. 168:207.
16. Cao, Y, Qin, L., Zhang, L., Safrit, J, and Ho, D. D. 1995. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N. Engl. J. Med. 332:201.
17. Arendrup, M., Nielsen, C. M., Hansen, J.-E. S., Mathiesen, L., Lindhardt, B., Scheibel, E. and Nielsen, J. O. 1992. Neutralizing antibodies against two HIV-1 strains in consecutively collected serum samples: cross neutralization and association to HIV-1 related disease. Scand. J. Infect. Dis. 24:21.
18. Prince A. M., Pascual, D., Kosolapov, L. B., Kurokawa, D., Baker, L. and Rubinstein, P. 1987. Prevalence, clinical significance, and strain specificity of neutralizing antibody to the human immunodeficiency virus. J. Infect. Dis. 156:268
19. Berman, P. W., Gregory, T. J., Riddle, L., Nakamura, G. R., Champe, M. A., Porter, J. P., Wurm, F. M., Hershberg, R. D., Cobb, K. E. and Eichberg, J. 1990. Protection of chimpanzees from infection by HIV-1 vaccination with recombinant glycoprotein 120 but not gp160. Nature 345:622.
20. Girard, M., Kieny, M. P., Pinter, A., Barre-Sinoussi, F., Nara, P., Kulbe, H., Kusumi, K., Chaput, A., Reinhart, T., Muchmore, E., Ronco, J., Kaczorek, M., Gomard, E., Gluckman, J.-C. and Fultz, P. N. 1991. Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc. Natl Acad. Sci. USA 88:542.
21. SF2. AIDS 9:1313.
22. Hanson, C. V. 1994. Measuring vaccine-induced HIV neutralization: report of a Workshop. AIDS Res. Hum. Retroviruses 10:645.
23. Matthew, T. J. 1994. The dilemma of neutralization resistance of HIV-1 field isolates and vaccine development. AIDS Res. Hum. Retroviruses 10:631.
24. Daar, E. S., Li, X. L., Moudgil, T. and Ho, D. D. 1990. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc. Natl Acad. Sci. USA 87:6574.
25. Moore, J. P., Cao, Y., Leu, J., Qin, L., Korber, B. and Ho, D. D. 1996. Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J. Virol. 70:427.
26. Moore, J. P., Cao, Y., Qing, L., Sattentau, Q. J., Pyati, J., Koduri, R., Robinson, J., Barbas, C. F., III, Burton, D. R. and Ho, D. D. 1995. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J. Virol. 69:101.
27. Hansen, J.-E. S., Nielsen, C., Arendrup, M., Olofsson, S., Mathiesen, L., Nielsen, J. O. and Clausen, H. 1991. Broadly neutralizing antibodies targeted to mucin-type carbohydrate epitopes of human immunodeficiency virus. J. Virol. 65:6461.
28. Conley, A. J., Gorny, M. K., Kessler, J. A., II, Boots, L. J., Lineberger, D., Emini, E. A., Ossorio, M., Koenig, S., Williams, C. and Zolla-Pazner, S. 1994. Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D. J. Virol. 68:6994.
29. Conley, A. J., Kessler II, J. A., Boots, L. J., Tung, J.-S., Arnold, B. A., Keller, P. M., Shaw, A. R. and Emini, E. A. 1994. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. Proc. Natl Acad. Sci. USA 91:3348.
30. Gorny M. K., Moore, J. P., Conley, A. J., Karwowska, S., Sodroski, J., Williams, C., Burda, S., Boots, L. J. and Zolla-Pazner, S. 1994. Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1. J. Virol. 68:8312.
31. Burton, D. R., Pyati, J., Koduri, R., Sharp, S. J., Thornton, G. B., Parren, P. W. H. I., Sawyer, L. S. W., Hendry, R. M., Dunlop, N., Nara, P. L., Lamacchia, M., Garratty, E., Stiehm, E. R., Bryson, Y. J., Cao, Y., Moore, J. P., Ho, D. D. and Barbas, C. F., III 1994. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266:1024.
32. Trkola, A., Pomales, A. B., Yuan, H., Korber, B., Maddon, P. J., Allaway, G. P., Katinger, H., Barbas, C. F., III, Burton, D. R., Ho, D. D. and Moore, J. P. 1995. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-lgG. J. Virol. 69:6609.
33. Wrin, T., Crawford, L., Sawyer, L., Weber, P., Sheppard, H. W. and Hanson, C. V. 1994. Neutralizing antibody response to autologous and heterologous isolates of human immunodeficiency virus. J. Acquired Immune Defic. Syndr. 7:211.
34. Nyambi, P. N., Nkengasong, J., Lewi, P., Andries, K., Janssens, W., Fransen, K., Heyndrickx, L., Piot, P. and van der Groen, G. 1996. Multivariate analysis of human immunodeficiency virus type 1 neutralization data. J. Virol. 70:6235.
35. Zolla-Pazner, S. and Sharpe, S. 1995. A resting cell assay for improved detection of antibody-mediated neutralization of HIV type I primary isolates. AIDS Res. Hum. Retroviruses 11:1449.
36. Lueck, M. D., Natuk, R. N., Myaghikh, M., Kaylan, N., Aldrich, K., Sinangil, F., Alipanah, S., Murthy, S. C. S., Chanda, P. K., Nigida, S., Markham, P. D., Zolla-Pazner, S., Steimer, K, Wade, M., Reitz, M. S., Jr, Arthur, L. O., Mizutani, S., Davis, A., Hung, P., Gallo, R. C., Eichberg, J. and Robert-Guroff, M. 1997. Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nature Med. 3:651.
37. Zolla-Pazner, S., Alving, C., Belshe, R., Berman, P., Burda, S., Chigurupati, P., Clements, M. L., Duliege, A.-M., Excler, J.-L., Hioe, C., Kahn, J., McElrath, M, J., Sharpe, S., Sinangil, F., Steimer, K., Walker, M. C., Wassef, N. and Xu, S. 1997, Neutralization of a clade B primary isolate by sera from human immunodeficiency virus-uninfected recipients of candidate AIDS vaccines. J. Infect. Dis. 175:764.
38. Johnson, V. A. and Byington, R. E. 1990. Quantitative assays for virus infectivity. In Aldovini, A. and Walker, B. D., eds, Techniques in HIV Research, p. 71. Stockton Press, New York.
39. Tyler, D. S., Stanley, S. D., Zolla-Pazner, S., Gorny, M. K., Shadduck, P. P., Langlois, A. J., Matthews, T. J., Bolognesi, D. P., Palker, T. J. and Weinhold, K. J. 1990. Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies. J. Immunol. 145:3276.
40. Xu, J.-Y., Gorny, M K., Palker, T., Karwowska, S. and Zolla-Pazner, S. 1991. Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies. J. Virol. 65:4832.
41. Karwowska, S., Gorny, M. K., Buchbinder, A., Gianakakos, V., Williams, C., Fuerst, T. and Zolla-Pazner, S. 1992. Production of human monoclonal antibodies specific for conformation and linear non-V3 epitopes of gp120. AIDS Res. Hum. Retroviruses 8:1099.
42. Gorny, M. K., Xu, J.-Y., Karwowska, S., Buchbinder, A. and Zolla-Pazner, S. 1993. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J. Immunol. 150:635.
43. McKeating, J. A., Bennett, J., Zolla-Pazner, S., Schutten, M., Ashelford, S., Brown, A. L. and Balfe, P. 1993. Resistance of a human serum-selected human immunodeficiency virus type 1 escape mutant to neutralization by CD4 binding site monoclonal antibodies is conferred by a single amino acid change in gp120. J. Virol 67:5216.
44. Forthal, D. N., Landucci, G., Gorny, M. K., Zolla-Pazner, S. and Robinson, W. E., Jr. 1995. Functional activities of 20 human immunodeficiency virus type 1 (HlV-1)-specific human monoclonal antibodies. AIDS Res. Hum. Retroviruses 11:1195.
45. Zolla-Pazner, S., O'Leary, J., Burda, S., Gorny, M. K., Kim, M., Mascola, J. and McCutchan, F. 1995. Serotyping of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry. J. Virol. 69:3807.
46. Laal, S., Burda, S., Sharpe, S. and Zolla-Pazner, S. 1993. A rapid, automated, microtitre assay for measuring neutralization for HIV-1. AIDS Res. Hum. Retroviruses 9:781.
47. Günthard, H. F., Gowland, P. L., Schüpbach, J., Fung, M. S. C., Boni, J., Liou, R.-S., Chang, N. T., Grob, P., Graepel, P., Braun, D. G, and Lüthy, R. 1994. A phase I/IIA clinical study with a chimeric mouse-human monoclonal antibody to the V3 loop of human immunodeficiency virus type 1 gp120. J. Infect. Dis. 170:1384.
48. Stomatatos, L., Zolla-Pazner, S., Gorny, M. K. and Cheng-Mayer, C. 1997. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells. Virology 229:360.
49. Hill, C. M., Deng, H. K., Unutmaz, D., Kewal-Ramani, V. N., Bastiani, L., Gorny, M. K., Zolla-Pazner, S, and Littman, D. R. 1997. Envelope glycoproteins from HIV-1, HIV-2, and SIV can use human CCR5 as co-receptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor. J. Virol., in press.
50. Fouts, T. R., Binley, J. M., Trkola, A., Robinson, J. E. and Moore, J. P. 1997. Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex. J. Virol. 71:2779.
51. Moore, J. P., Trkola, A., Korber, B., Boots, L. J., Kessler II, J. A., McCutchan, F. E., Mascola, J., Ho, D. D., Robinson, J. and Conley, A. J. 1995. A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B. J. Virol. 69:122.
52. Cotropia, J., Ugen, K. E., Kliks, S., Broliden, K., Broliden, P.-A., Hoxie, J. A., Srikartan, V., Williams, W. V. and Weiner, D. B. 1996. A human monoclonal antibody to HIV-1 gp41 with neutralizing activity against diverse laboratory isolates. J. Acquired Immune Defic. Syndr. and Hum. Retrovirol. 12:221.
53. Muster, T., Steindl, F., Purtscher, M., Trkola, A., Klima, A., Himmler, G., Ruker, F. and Katinger, H. 1993. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67:6642.
54. Mascola, J. R., Louwagie, J., McCutchan, F. E., Fischer, C. L., Hegerich, P. A., Wagner, K. F., Fowler, A. K., McNeil, J. G. and Burke, D. S. 1994. Two antigenically distinct subtypes of human immunodeficiency virus type 1: virus genotype predicts neutralization serotype. J. Infect. Dis. 169:48.
55. Laal, S., Burda, S., Gorny, M. K., Karwowska, S., Buchbinder, A. and Zolla-Pazner, S. 1994. Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies. J. Virol. 68:4001.
56. Ho, D. D., McKeating, J. A., Li, X. L., Moudgil, T., Daar, E. S., Sun, N. C. and Robinson, J. E. 1991. Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody. J. Virol. 65:489.
57. Ho, D. D., Fung, M. S. C., Cao, Y, Li, X. L., Sun, C., Chang, T. W. and Sun, N. C. 1991. Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody. Proc. Natl Acad. Sci. USA 88:8949.
58. Posner, M. R., Cavacini, L. A., Emes, C. L., Power, J. and Byrn, R. 1993. Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120. J. Acquired Immune Defic. Syndr. 6:7.
59. Robinson, W. E., Kawamura, T, Gorny, M. K., Lake, D., Xu, J.-Y., Matsumoto, Y, Sugano, T., Masuho, Y., Mitchell. W. M., Hersh. E. and Zolla-Pazner, S. 1990. Human monoclonal antibodies to the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 enhance HIV-1 infection In vitro. Proc. Natl Acad. Sci. USA 87:3185.
60. Nara, P. L., Garrity, R. R. and Goudsmit, J. 1991. Neutralization of HIV-1: a paradox of humoral proportions. FASEB J. 5:2437.
61. Stomatatos, L., Werner, A. and Cheng-Mayer, C. 1994. Differential regulation of cellular tropism and sensitivity to soluble CD4 neutralization by the envelope gp120 of human immunodeficiency virus type 1. J. Virol. 68:4973.
62. Bou-Habib, D. C., Roderiquez, G., Oravecz, T., Berman, P. W., Lusso, P. and Norcross, M. A. 1994. Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. J. Virol. 68:6006.
63. Sattentau, Q. J. and Moore, J P. 1995. HIV-1 neutralization is determined by epitope exposure on the gp120 oligomer. J. Exp. Med 182:185.
64. Ebenbichler, C., Westervelt, P., Carrillo, A., Henkel, T., Johnson, D. and Ratner, L. 1993. Structure-function relationships of the HIV-1 envelope V3 loop tropism determinant: evidence for two distinct conformations. AIDS 7:639.
65. Zhong, P., Peeters, M., Janssens, W., Fransen, K., Heyndrickx, L., Vanham, G., Willems, B., Piot, P. and van der Groen, G. 1995. Correlation between genetic and biological properties of biologically cloned HIV type 1 viruses representing subtypes A, B, and D. AIDS Res. Hum. Retroviruses 11:239.
66. Stomatatos, L. and Cheng-Mayer, C. 1995. Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerication and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virionsotuble receptor binding. J. Virol. 69:6191.
67. Clements, G. J., Price-Jones, M. J., Stephens, P. E., Sutton, C., Schulz, T. F., Clapham, P. R., McKeating, J. A., McClure, M. O., Thomson, S., Marsh, M., Kay, J., Weiss, R. A. and Moore, J. P. 1991. The V3 loops of the HIV-1 and HIV-2 surface glycoproteins contain proteolytic cleavage sites: a possible function in viral fusion? AIDS Res. Hum. Retroviruses 7:3.
68. Dimmock, N. J. 1995. Update on the neutralization of animal viruses. Rev. Med. Virol. 5:165.
69. Hwang, S., Boyle, T., Lyerly, H. and Cullen, B. 1991. Identification of the V3 loop as the primary determinant of cell tropism in HIV-1. Science 253:71.
70. Choe, H., Farzan, M., Sun, Y., Sullivan, N., Rollins, B., Ponath, P. D., Wu, L., Mackay, C. R., LaRosa, G., Newman, W., Gerard, N., Gerard, C. and Sodroski, J. 1996. The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85:1135.
71. Bandres, J. C., Wang, Q. F., O'Leary, J., Baleaux, F, Amara, A., Arenzana-Seisdedos, F., Hoxie, J. A., Zolla-Pazner, S. and Gorny, M. K 1997. HIV-envelope binds to CXCR4 independent of CD4 and this binding can be enhanced by combination with soluble CD4 or by HIV envelope deglycosylation. Submitted.
72. Richardson, T. M., Jr, Stryjewski, B. L., Broder, C. C., Hoxie, J. A., Mascola, J. R., Earl, P. L. and Doms, R. W. 1996. Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein. J. Virol. 70:753.
73. Zhou, J. Y. and Montefiori, D. C. 1997. Antibody-mediated neutralization of primary isolates of human immunodeficiency virus type 1 in peripheral blood mononuclear cells is not affected by the initial activation state of the cells. J. Virol. 71:2512.
74. Hioe, C. E., Burda, S., Chigurupati, P., Xu, S. and Zolla-Pazner, S. 1997. The resting cell neutralization assay for HIV-1 primary isolates. Methods: A Companion to Methods in Enzymology, in press.